Invokana (canagliflozin) is in a new class of drugs used to treat type 2 diabetes, called sodium-glucose cotransporter-2 (SGLT2) inhibitors. Invokana’s use has been linked to a dangerous medical condition called ketoacidosis. Diabetic ketoacidosis often requires hospitalization and can be fatal. If you or someone you love has suffered ketoacidosis … [Read more...]
Health Canada has Initiated Safety Review of Invokana and Forxiga
On June 22, 2015, Health Canada announced that it has initiated a safety review of sodium-glucose cotransporter-2 (SGLT2) inhibitors Invokana (canagliflozin) and Forxiga (dapagliflozin), and their risk of causing diabetic acidosis. SGLT2 inhibitors are a new class of drugs used to treat type 2 diabetes. Invokana was approved by the U.S. Food and … [Read more...]
Invokana Linked to Heart Attack, Kidney Problems, and Ketoacidosis
If you have suffered a heart attack, other cardiovascular problems, kidney damage or ketoacidosis while taking Invokana (canagliflozin) or Invokamet for Type 2 diabetes, your medication may be the cause. Invokana was approved by the U.S. Food and Drug Administration (FDA) in March 2013, to treat Type 2 diabetes. It was the first in a new class of … [Read more...]
Recent Comments